FDA Issues Class I Recall for RelayPro Thoracic Stent Graft Following Three Patient Deaths
Deployment failure during aortic repair may require emergency open surgery
The U.S. Food and Drug Administration (FDA) has issued a Class I recall for certain RelayPro Thoracic Stent-Graft Systems manufactured by Bolton Medical, citing a deployment defect that has been associated with three patient deaths.
FDA’s most serious recall classification indicates that continued use of the affected devices may cause serious injury or death.
About the Device
The RelayPro Thoracic Stent-Graft System is used to treat diseases of the thoracic aorta, including thoracic aortic aneurysms, aortic dissections, and traumatic aortic injuries.
The minimally invasive device is intended to reinforce weakened sections of the aorta while maintaining blood flow without requiring open chest surgery.
Affected Devices
The recall affects the RelayPro Thoracic Stent Graft System with an N4 Non-Bare Stent Configuration with a diameter of 32mm and larger.
Healthcare facilities are instructed to immediately discontinue use, isolate affected inventory, and return the devices to the manufacturer.
What Is the Problem?
According to Bolton Medical, the device may fail during deployment because the proximal clasp can become disconnected from the outer control tube, preventing release of the stent graft from the delivery system.
The problem becomes apparent only after deployment has begun. If the malfunction occurs, the stent graft cannot be released properly, the device cannot be recaptured, and no device-based bailout method is available.
Potential consequences include procedure delays, stent graft displacement, failure to deploy the graft, emergency conversion to open surgical repair, and death.
Reported Adverse Events
As of April 23, the manufacturer reported three patient deaths. One death was due to aortic perforation and the other two followed a conversion to open chest surgery complicated by stroke.
Recommended Actions
Healthcare providers should immediately discontinue use of affected RelayPro systems, quarantine affected inventory, notify any facilities that received transferred devices, and return affected products to the manufacturer. Direct any manufacturer communication to Terumo Aortic at Market_Actions-TMC@terumomedical.com.
Links
Read the FDA Announcement here.
FDA Approves Wilserdly for Advanced Breast Cancer
Genentech’s oral estrogen receptor antagonist significantly extends progression-free survival, accompanied by FDA authorization of a liquid biopsy companion diagnostic.On November 16, 2026, the U.S. Food and Drug Administration (FDA) approved giredestrant (Wilserdly,...
FDA Pivots from Artificial Intelligence to Super Intelligence
A Regulatory Solution in Search of a ProblemFDA's implementation of a presidential terminology mandate raises questions about scientific accuracy, regulatory consistency, and the responsible use of limited public health resources.Beginning November 16, 2026, the U.S....
Science, Politics, Special Interests, and FDA Independence
Former Insiders Challenge the Administration's Health AgendaFormer FDA Commissioner Marty Makary and former Kennedy adviser Calley Means allege that political and commercial pressures interfered with federal health priorities. Their accounts raise questions about...
When Preventable Diseases Return
Diseases once brought under control through vaccination have returned with devastating consequences. Historical outbreaks in the former Soviet Union and Japan offer important lessons as the United States confronts its largest measles resurgence in decades.For...
Intersurgical 22mm Smoothbore Breathing Tubes and Systems
FDA Issues Early Alert for Intersurgical Breathing Systems Over Potential Ventilation Failure. Manufacturing defect may cause breathing tube connectors to separate during use, potentially interrupting ventilation and exposing patients to serious injury or death.The...
FDA Early Alert: Teleflex/Arrow Guidewire
Affected guidewires and catheter products may release hydrophilic polymer particles into the bloodstream, potentially causing serious injury or death. No serious injuries or deaths have been reported.The U.S. Food and Drug Administration (FDA) has issued an Early...

